Figure 5. COX-2 inhibition prevents CCM lesions in Pdcd10^BECKO mice.

(A) Prominent lesions are present in the cerebellum and cerebrum of P13 Pdcd10^BECKO mice. Intragastric administration of 40 mg/kg celecoxib for 4 consecutive days at P6 to P9 suppressed lesion formation. Quantification of lesion volumes by micro-CT analysis from mice at P13 treated with celecoxib or vehicle (SEM, n = 7 mice in each group). (B) Hematoxylin and eosin (pink and purple) or GFAP (red) staining of cerebral (hippocampal area) and cerebellar sections from Pdcd10^BECKO mice after treatment with celecoxib or vehicle (n = 3). (C) Prominent lesions are present in the cerebellum and cerebrum of P80 Pdcd10^BECKO mice. Oral gavage administration of 40 mg/kg celecoxib for 15 consecutive days at P55 to P70 suppressed lesion formation. Quantification of lesion volumes by micro-CT analysis from mice at P80 treated with celecoxib or vehicle (SEM, n = 12 or 14 mice in each group). (D) Hematoxylin and eosin (pink and purple) or GFAP (red) staining of cerebral (hippocampal area) and cerebellar sections from Pdcd10^BECKO mice after treatment with celecoxib or vehicle (n = 3). (E and F) Quantification of Vegfa (E) or Nos3 (F) mRNA levels in P80 Pdcd10^BECKO spinal cords after treatment with celecoxib or vehicle from experiments in (C) (SEM, n = 7 or 9 mice in each group). Data are mean ± SEM. *P < 0.05, **P < 0.01, as determined by Student’s t test. Scale bars: 1 mm (H&E), 200 μm (GFAP) (B and D).